Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities

NCT04860258 is registered in ClinicalTrials.gov with CureVac as lead sponsor.

NCT NCT04860258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04860258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities
Lead sponsor
CureVac
Phase
Phase 3
Overall status
Terminated
Start date
April 22, 2021
Completion date
September 21, 2021
Enrollment
129 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, covid19, sars-cov-2, severe acute respiratory syndrome